Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 1651 - 1675 of 2070 in total
Experimental
Matched Iupac: … 8-oxatricyclo[7.4.0.0^{2,7}]trideca-1(9),2(7),3,5,10,12-hexaene-6,10-dicarboxylic acid …
Spiperone is a dopamine antagonist that binds dopamine and serotonin receptors.
Investigational
Matched Iupac: … 8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one …
Investigational
PF-232798 is under investigation in clinical trial NCT01140425 (Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects).
Investigational
Matched Iupac: … azabicyclo[3.2.1]octan-8-yl]propyl]acetamide ... fluorophenyl)-3-[(1R,3S,5S)-3-[2-methyl-5-(2-methylpropanoyl)-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-1-yl]-8- …
Investigational
NGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.
Investigational
Matched Iupac: … (2S)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decan-3-one …
NM-3 has been used in trials studying the treatment of Neoplasms.
Investigational
Matched Iupac: … 2-(8-hydroxy-6-methoxy-1-oxo-1H-isochromen-3-yl)propanoic acid …
Potent reversible inhibitor of phenylethanolamine N-methyltransferase.
Experimental
Potent activator of the adenylate cyclase system and the biosynthesis of cyclic AMP. From the plant Coleus forskohlii. Has antihypertensive, positive inotropic, platelet aggregation inhibitory, and smooth muscle relaxant activities; also lowers intraocular pressure and promotes release of hormones from the pituitary gland.
Experimental
Investigational
Investigational
Vilobelimab is a chimeric monoclonal immunoglobulin G4 (IgG4) antibody that binds to the soluble form of human C5a with high affinity. It consists of mouse anti-human complement factor 5a (C5a) monoclonal binding sites (variable regions of heavy and light chain regions) and human gamma 4 heavy chain and light kappa...
Investigational
Experimental
Matched Iupac: … 3-{2,4,7-trioxo-8-[(2S,3S,4R)-2,3,4,5-tetrahydroxypentyl]-1,2,3,4,7,8-hexahydropteridin-6-yl}propanoic …
9 Cuab30 has been used in trials studying the treatment and prevention of HER2/Neu Positive, HER2/Neu Negative, No Evidence of Disease, Estrogen Receptor Negative, and estrogen receptor positive, among others.
Investigational
Matched Iupac: … (2E,4E,6Z)-3,7-dimethyl-8-[(1E)-1,2,3,4-tetrahydronaphthalen-1-ylidene]octa-2,4,6-trienoic acid …
Experimental
Matched Iupac: … 5-ethyl-8-oxo-2H,5H,8H-[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid …
Experimental
Matched Iupac: … 8-thia-4,6-diazatricyclo[7.4.0.0^{2,7}]trideca-1(9),2(7),5-trien-3-one …
ME-344 has been used in trials studying the treatment of Solid Tumors.
Investigational
Matched Iupac: … (3R,4S)-3,4-bis(4-hydroxyphenyl)-8-methyl-3,4-dihydro-2H-1-benzopyran-7-ol …
Racemetyrosine is under investigation in clinical trial NCT03512756 (A Randomized Phase 2/3 Multi-center Study of SM-88 in Patients With Metastatic Pancreatic Cancer).
Investigational
Investigational
BNT162b1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162b1 is a nucleoside modified mRNA (modRNA) vaccine encoding the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein together with a "foldon" trimerization domain derived from T4 fibritin...
Investigational
Matched Description: … [L15017, L15022] BNT162b1 received fast track designation by the FDA on July 13, 2020.[L15027] …
Experimental
Matched Iupac: … 1-[(2E,4E,6E,8R)-8-hydroxy-6-methyldodeca-2,4,6-trienoyl]pyrrolidin-2-one …
Displaying drugs 1651 - 1675 of 2070 in total